Literature DB >> 24013571

Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families.

Jerry H Kim1, Gail P Jarvik, Brian L Browning, Ramakrishnan Rajagopalan, Adam S Gordon, Mark J Rieder, Peggy D Robertson, Deborah A Nickerson, Nickla A Fisher, Philip M Hopkins.   

Abstract

BACKGROUND: About half of malignant hyperthermia (MH) cases are associated with skeletal muscle ryanodine receptor 1 (RYR1) and calcium channel, voltage-dependent, L type, α1S subunit (CACNA1S) gene mutations, leaving many with an unknown cause. The authors chose to apply a sequencing approach to uncover causal variants in unknown cases. Sequencing the exome, the protein-coding region of the genome, has power at low sample sizes and identified the cause of over a dozen Mendelian disorders.
METHODS: The authors considered four families with multiple MH cases lacking mutations in RYR1 and CACNA1S by Sanger sequencing of complementary DNA. Exome sequencing in two affecteds per family, chosen for maximum genetic distance, were compared. Variants were ranked by allele frequency, protein change, and measures of conservation among mammals to assess likelihood of causation. Finally, putative pathogenic mutations were genotyped in other family members to verify cosegregation with MH.
RESULTS: Exome sequencing revealed one rare RYR1 nonsynonymous variant in each of three families (Asp1056His, Val2627Met, Val4234Leu), and one CACNA1S variant (Thr1009Lys) in the fourth family. These were not seen in variant databases or in our control population sample of 5,379 exomes. Follow-up sequencing in other family members verified cosegregation of alleles with MH.
CONCLUSIONS: The authors found that using both exome sequencing and allele frequency data from large sequencing efforts may aid genetic diagnosis of MH. In a sample selected by the authors, this technique was more sensitive for variant detection in known genes than Sanger sequencing of complementary DNA, and allows for the possibility of novel gene discovery.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24013571      PMCID: PMC4115638          DOI: 10.1097/ALN.0b013e3182a8a998

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  39 in total

Review 1.  Generation of diversity in retroviruses.

Authors:  R A Katz; A M Skalka
Journal:  Annu Rev Genet       Date:  1990       Impact factor: 16.830

2.  A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees.

Authors:  R L Robinson; N Monnier; W Wolz; M Jung; A Reis; G Nuernberg; J L Curran; K Monsieurs; P Stieglitz; L Heytens; R Fricker; C van Broeckhoven; T Deufel; P M Hopkins; J Lunardi; C R Mueller
Journal:  Hum Mol Genet       Date:  1997-06       Impact factor: 6.150

3.  Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle.

Authors:  N Monnier; V Procaccio; P Stieglitz; J Lunardi
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

4.  Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population.

Authors:  Nyamkhishig Sambuughin; Heather Holley; Sheila Muldoon; Barbara W Brandom; Astrid M de Bantel; Joseph R Tobin; Tom E Nelson; Lev G Goldfarb
Journal:  Anesthesiology       Date:  2005-03       Impact factor: 7.892

5.  Incidence of malignant hyperthermia in Denmark.

Authors:  H Ording
Journal:  Anesth Analg       Date:  1985-07       Impact factor: 5.108

6.  A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group.

Authors: 
Journal:  Br J Anaesth       Date:  1984-11       Impact factor: 9.166

7.  Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q.

Authors:  R C Levitt; A Olckers; S Meyers; J E Fletcher; H Rosenberg; H Isaacs; D A Meyers
Journal:  Genomics       Date:  1992-11       Impact factor: 5.736

8.  Localization of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families.

Authors:  D E Iles; F Lehmann-Horn; S W Scherer; L C Tsui; D Olde Weghuis; R F Suijkerbuijk; L Heytens; G Mikala; A Schwartz; F R Ellis
Journal:  Hum Mol Genet       Date:  1994-06       Impact factor: 6.150

9.  Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1.

Authors:  R Sudbrak; V Procaccio; M Klausnitzer; J L Curran; K Monsieurs; C van Broeckhoven; R Ellis; L Heyetens; E J Hartung; G Kozak-Ribbens
Journal:  Am J Hum Genet       Date:  1995-03       Impact factor: 11.025

10.  Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia.

Authors:  D H MacLennan; C Duff; F Zorzato; J Fujii; M Phillips; R G Korneluk; W Frodis; B A Britt; R G Worton
Journal:  Nature       Date:  1990-02-08       Impact factor: 49.962

View more
  23 in total

Review 1.  The long tail and rare disease research: the impact of next-generation sequencing for rare Mendelian disorders.

Authors:  Tony Shen; Ariel Lee; Carol Shen; C Jimmy Lin
Journal:  Genet Res (Camb)       Date:  2015-09-14       Impact factor: 1.588

2.  Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of RYR1, CACNA1S and STAC3 variants.

Authors:  Senthilkumar Sadhasivam; Barbara W Brandom; Richard A Henker; John J McAuliffe
Journal:  Pharmacogenomics       Date:  2019-09       Impact factor: 2.533

3.  RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms.

Authors:  Paul J Isackson; Jianxin Wang; Mohammad Zia; Paul Spurgeon; Adrian Levesque; Jonathan Bard; Smitha James; Norma Nowak; Tae Keun Lee; Georgirene D Vladutiu
Journal:  Pharmacogenomics       Date:  2018-10-16       Impact factor: 2.533

4.  Genetic epidemiology of malignant hyperthermia in the UK.

Authors:  D M Miller; C Daly; E M Aboelsaod; L Gardner; S J Hobson; K Riasat; S Shepherd; R L Robinson; J G Bilmen; P K Gupta; M-A Shaw; P M Hopkins
Journal:  Br J Anaesth       Date:  2018-08-17       Impact factor: 9.166

5.  Malignant hyperthermia and the clinical significance of type-1 ryanodine receptor gene (RYR1) variants: proceedings of the 2013 MHAUS Scientific Conference.

Authors:  Sheila Riazi; Natalia Kraeva; Sheila M Muldoon; James Dowling; Clara Ho; Maria-Alexandra Petre; Jerome Parness; Robert T Dirksen; Henry Rosenberg
Journal:  Can J Anaesth       Date:  2014-09-05       Impact factor: 5.063

6.  In Reply.

Authors:  Philip M Hopkins; Dorota Fiszer; Marie-Anne Shaw; Daniel Roiz de Sa
Journal:  Anesthesiology       Date:  2016-02       Impact factor: 7.892

Review 7.  Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.

Authors:  Sheila Riazi; Natalia Kraeva; Philip M Hopkins
Journal:  Anesthesiology       Date:  2018-01       Impact factor: 7.892

8.  PGRNseq: a targeted capture sequencing panel for pharmacogenetic research and implementation.

Authors:  Adam S Gordon; Robert S Fulton; Xiang Qin; Elaine R Mardis; Deborah A Nickerson; Steve Scherer
Journal:  Pharmacogenet Genomics       Date:  2016-04       Impact factor: 2.089

9.  Exome sequencing: one small step for malignant hyperthermia, one giant step for our specialty--why exome sequencing matters to all of us, not just the experts.

Authors:  Peter Nagele
Journal:  Anesthesiology       Date:  2013-11       Impact factor: 7.892

Review 10.  Triadopathies: an emerging class of skeletal muscle diseases.

Authors:  James J Dowling; Michael W Lawlor; Robert T Dirksen
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.